The Union Health Ministry has proposed amendments to the Drugs Rules, 1945, to provide regulatory flexibility to certain categories of drugs, including medicinal gases, empty gelatin capsules and disinfectant fluids. The step was taken after representations from stakeholders about whether certain requirements under the revised Schedule M, notified in December 2023, apply to these products.
The proposed amendments seek to continue exemptions available to these categories under the earlier version of Schedule M, according to a draft Gazette notification issued by the ministry. The draft notification, GSR 985(E), dated 6 November, has been published in the Gazette of India to invite objections and suggestions from stakeholders and members of the public.
The matter was deliberated upon by the Drugs Technical Advisory Board, known as the DTAB, at its 93rd meeting held on 16 February 2026. The board observed that certain requirements under the revised Schedule M might not be relevant to the manufacturing processes of medicinal gases, empty gelatin capsules and disinfectant fluids, officials said.
Why Schedule M relief is proposed
Schedule M sets out good manufacturing practices for drugs made in India. The revised version, notified through GSR 922(E) on 28 December 2023, raised the bar on premises, equipment, quality control and documentation. Industry groups then told the ministry that some of those requirements do not fit the way medicinal gases, empty gelatin capsules and disinfectant fluids are actually made.
Medicinal gases are produced and filled under conditions that differ from tablet or syrup lines, and empty gelatin capsules are an intermediate product rather than a finished medicine. Disinfectant fluids are made for external use, and their production does not follow the same steps as a drug taken by mouth. The board accepted that some Schedule M provisions may not be relevant to those processes, and it recommended that the earlier exemptions continue.
The proposed amendment seeks to ensure that regulatory requirements are appropriately aligned with the nature and manufacturing processes of specific categories of drugs, while maintaining effective regulatory oversight. The ministry has said the proposal does not dilute the applicable standards of quality, safety or regulatory oversight, and that the change is about fit rather than about lowering the bar.
Schedule M and the wider drug rules
The ministry issued the draft through the Gazette to invite public comment before finalisation. Both the Schedule M proposal and a separate proposal on good storage and distribution practices are currently in draft form, and neither has a fixed date for coming into force. The final Gazette notifications are expected after the comment period closes and the responses have been considered.
The separate draft proposes incorporating Good Storage and Distribution Practices, known as GSDP, into the Drugs Rules, 1945. The guidelines were developed on the basis of recommendations by the Central Drugs Standard Control Organisation, known as the CDSCO. They cover procurement, purchasing, storage, transportation, documentation and record keeping, and they are designed to preserve the quality, safety, efficacy and integrity of pharmaceutical products at every link in the distribution chain.
The ministry has also proposed bringing antimicrobial drugs under the regulatory framework for new drugs, to strengthen quality checks amid growing concern over antimicrobial resistance. Under that proposal, antimicrobials would be included in the definition of a new drug, and manufacturers would need prior permission from the Central Licensing Authority before approaching the state licensing authority for a manufacturing licence. The two drafts were published together, and both are open for stakeholder feedback.
What the Schedule M change would mean
For makers of medicinal gases, empty gelatin capsules and disinfectant fluids, the proposal would remove requirements that were written for other kinds of production. The licensing authorities would be able to take product specific decisions based on scientific and practical considerations, rather than applying the same checklist to every manufacturer regardless of what it makes.
The change would not remove the need for licences, inspections or quality checks. The products would still have to meet the standards that apply to them, and the regulators would still be able to act against manufacturers that fall short. The proposal changes which Schedule M provisions apply, and it leaves the rest of the regulatory framework in place.
The draft is now open for objections and suggestions. Industry groups, patient groups and members of the public can respond, and the ministry will consider those responses before deciding whether to finalise the amendment as drafted or to change it.

